$TXG News

10x Genomics Partners With Lausanne University Hospital On Diagnostic Applications Of Single Cell And Spatial Technologies For Cancer Care

Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $40

10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026

Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $50

Does 10x Genomics (TXG) Leaving Russell Value Indexes Reframe Its Growth Versus Profitability Story?

Is 10x Genomics (TXG) Overvalued Following Its Earnings Beat?

Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $37

10x Genomics (TXG) Stock Looks Reasonable On Cash Flow But Rich On Sales

Life Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG)

Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $45

Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $42

Why Is 10x Genomics (TXG) Stock Soaring Today

Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $40

10x Genomics (TXG): Buy, Sell, or Hold Post Q1 Earnings?

10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer

10x Genomics Partners With Cleveland Clinic Over Research In Novel Diagnostics For Bladder Cancer

10x Genomics: Temporary Pain, Long-Term Gain As Atera Rollout Approaches

10x Genomics Acquires Proteintech Genomics; Financial Terms Undisclosed

10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript

10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors.